Back to Search Start Over

Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.

Authors :
Chen, Yunn-Yi
Chen, Yunn-Yi
Ma, Lin
Beck, Andrew
Cummings, Steven
Kerlikowske, Karla
Vachon, Celine
Yaghjyan, Lusine
Tamimi, Rulla
Bertrand, Kimberly
Scott, Christopher
Jensen, Matthew
Pankratz, V
Brandt, Kathy
Visscher, Daniel
Norman, Aaron
Couch, Fergus
Shepherd, John
Fan, Bo
Chen, Yunn-Yi
Chen, Yunn-Yi
Ma, Lin
Beck, Andrew
Cummings, Steven
Kerlikowske, Karla
Vachon, Celine
Yaghjyan, Lusine
Tamimi, Rulla
Bertrand, Kimberly
Scott, Christopher
Jensen, Matthew
Pankratz, V
Brandt, Kathy
Visscher, Daniel
Norman, Aaron
Couch, Fergus
Shepherd, John
Fan, Bo
Source :
Breast Cancer Research and Treatment; vol 165, iss 2
Publication Year :
2017

Abstract

PURPOSE: We examined the associations of mammographic breast density with breast cancer risk by tumor aggressiveness and by menopausal status and current postmenopausal hormone therapy. METHODS: This study included 2596 invasive breast cancer cases and 4059 controls selected from participants of four nested case-control studies within four established cohorts: the Mayo Mammography Health Study, the Nurses Health Study, Nurses Health Study II, and San Francisco Mammography Registry. Percent breast density (PD), absolute dense (DA), and non-dense areas (NDA) were assessed from digitized film-screen mammograms using a computer-assisted threshold technique and standardized across studies. We used polytomous logistic regression to quantify the associations of breast density with breast cancer risk by tumor aggressiveness (defined as presence of at least two of the following tumor characteristics: size ≥2 cm, grade 2/3, ER-negative status, or positive nodes), stratified by menopausal status and current hormone therapy. RESULTS: Overall, the positive association of PD and borderline inverse association of NDA with breast cancer risk was stronger in aggressive vs. non-aggressive tumors (≥51 vs. 11-25% OR 2.50, 95% CI 1.94-3.22 vs. OR 2.03, 95% CI 1.70-2.43, p-heterogeneity = 0.03; NDA 4th vs. 2nd quartile OR 0.54, 95% CI 0.41-0.70 vs. OR 0.71, 95% CI 0.59-0.85, p-heterogeneity = 0.07). However, there were no differences in the association of DA with breast cancer by aggressive status. In the stratified analysis, there was also evidence of a stronger association of PD and NDA with aggressive tumors among postmenopausal women and, in particular, current estrogen+progesterone users (≥51 vs. 11-25% OR 3.24, 95% CI 1.75-6.00 vs. OR 1.93, 95% CI 1.25-2.98, p-heterogeneity = 0.01; NDA 4th vs. 2nd quartile OR 0.43, 95% CI 0.21-0.85 vs. OR 0.56, 95% CI 0.35-0.89, p-heterogeneity = 0.01), even though the interaction was not significan

Details

Database :
OAIster
Journal :
Breast Cancer Research and Treatment; vol 165, iss 2
Notes :
application/pdf, Breast Cancer Research and Treatment vol 165, iss 2
Publication Type :
Electronic Resource
Accession number :
edsoai.on1410328594
Document Type :
Electronic Resource